Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
AstraZeneca
Johnson and Johnson
Mallinckrodt
McKinsey

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,278,292

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,278,292 protect, and when does it expire?

Patent 8,278,292 protects PICATO and is included in one NDA.

This patent has thirty-one patent family members in twenty countries.

Summary for Patent: 8,278,292
Title:Therapeutic compositions
Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.
Inventor(s): Brown; Marc Barry (Watford, GB), Crowthers; Michael Edward Donald (Hillsborough, GB), Nazir; Tahir (Isleworth, GB)
Assignee: LEO Laboroatories Limited (Dublin, IE)
Application Number:12/097,258
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,278,292
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 8,278,292

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-002 Jan 23, 2012 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,278,292

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0525680.5Dec 16, 2005
PCT Information
PCT FiledDecember 18, 2006PCT Application Number:PCT/GB2006/004739
PCT Publication Date:June 21, 2007PCT Publication Number: WO2007/068963

International Family Members for US Patent 8,278,292

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006325244   Start Trial
Brazil PI0619919   Start Trial
Canada 2634073   Start Trial
Cyprus 1115292   Start Trial
Denmark 1988877   Start Trial
Eurasian Patent Organization 018545   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Baxter
Medtronic
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.